Bei Akademie registrieren
Argenx, NL0010832176

Argenx stock at EUR 732.70 ahead of the Xetra open today

Published on 10/19/2026 at 07:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The investor materials highlight approved immunology therapies and list VYVGART products. At Lang & Schwarz the stock trades pre-market at EUR 732.70 on October 19, 2026.

Business model and morning price

  • argenx's investor materials highlight approved immunology therapies in the United States, including VYVGART and VYVGART Hytrulo.
  • On October 19, 2026, the relevant benchmark context is the Euro Stoxx 50.
  • Argenx stock trades pre-market at EUR 732.70 at 7:56 a.m. CEST at Lang & Schwarz on October 19, 2026.
Extremmakro: Iridisierende blaue und violette Flüssigkeitstropfen auf einem Glasobjektträger, kristallscharfe Mitte mit weichem Bokeh, wissenschaftliche Abstraktion
Argenx NL0010832176 Extremmakro zeigt irisierende Flüssigkeitstropfen auf einem wissenschaftlichen Glas-Objektträger unter Laborlicht, Illustration mit AI erstellt.

argenx's portfolio includes approved immunology therapies in the United States, including VYVGART and VYVGART Hytrulo, according to the company's investor materials. Argenx stock trades pre-market at EUR 732.70 at 7:56 a.m. CEST at Lang & Schwarz on October 19, 2026.

Ahead of the Xetra open

The indication is being monitored before the 9:00 a.m. CEST Xetra open. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of argenx stock.

Business and market setting

argenx develops an immunology portfolio centered on approved therapies in the U.S. market, as described by the company. On October 19, 2026, the relevant benchmark context is the Euro Stoxx 50. Market context: Market report Euro Stoxx 50.

More news and analysis on Argenx stock

Disclaimer...
en | NL0010832176 | ARGENX | boerse | 70357844 | bgmi